Designations for Daiichi Sankyo and AstraZeneca's ENHERTU include patients with HER2 expressing metastatic solid tumors and HER2 positive metastatic colo...
ImmunoGen to Receive $34 Million1 in Upfront and Near-Term Milestone Payments and is Eligible to Receive Potential Regulatory and Commercial Milestone Paym...
Malaysia Healthcare Travel Council (MHTC) is proud to announce a pilot programme, "Rejuvenate with Malaysia Healthcare," which aims to cultivate Malaysia a...
Australia's Monash University and American firm Moderna have announced the establishment of the Monash-Moderna Quantitative Pharmacology Accelerator (MMQPA...
APHRS and the Society for Cardiac Robotic Navigation will host a joint session on September 2, 2023, during the APHRS annual congress. The joint session in...
The Peter Mac Cancer Center is a world leading cancer research, education and treatment center and Australia’s only public health service dedicated t...
Uro-G offers a viewing angle of 120°, both 210° upward and 130° downward motion angles, and a 90° angle of rotation clockwise and countercl...
LUNAR-FLU collaboration with CSL Seqirus achieves additional $17.5 million development milestone Arcturus Therapeutics Holdings Inc. (the “C...
The consistency evaluation of generic drugs evaluates approved generic drugs based on the principle that generic drugs need to reach the same level of qual...
GenScript Biotech, the world's leading life-science research tools and services provider, and T-MAXIMUM Biotech, a biotechnology company pioneering univers...
Agilent Technologies Inc. (NYSE: A) announced the opening of a new full-scale Integrated Biology Center located at Monash University in Malaysia...
Poseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products using genetic enginee...
Nandini Piramal, Chairperson, Piramal Pharma Limited said, "We had a positive start to the new financial year with healthy revenue growth and improvem...
Somatostatin receptor 2 (SSTR2) is found in 81% of primary, recurrent, and metastatic NPC patients. EBTATE, the first patented and only long-acting peptide...
© 2024 Biopharma Boardroom. All Rights Reserved.
